Determination of Anti-Malignin Antibody and Malignin in 1,026 Cancer Patients and Controls: Relation of Antibody to Survival

Discrimination of Breast Cancer by Anti-Malignin Antibody Serum Test in Women Undergoing Biopsy

“…In addition, some patients may be AMAS positive, because they harbor occult malignancies other than breast cancer. In a series of 1,026 patients and controls, of those initially AMAS ''false positive,'' 23% were diagnosed with cancer within 19 months (12). The contribution of occult malignancy to confounding remains uncertain, because the extent to which a known positive AMAS test contributed to detection bias is unclear, nor was the number of AMAS-negative patients who developed cancer reported.…”

“…The molecule has been identified as a moiety of a larger (250 kDa) brain membrane glycoprotein, which seems hypoglycosylated in glioblastoma cells (8). Elevated titers of anti-malignin-binding antibodies have been reported in serum from patients with a variety of malignancies (9) and the anti-malignin antibody serum (AMAS) test has been reported to provide specificity and sensitivity of >95% for cancers, regardless of type (10)(11)(12). A recent study (13) found 97% sensitivity and 64% specificity in women with suspicious mammograms and/or palpable breast masses coming for a needle biopsy.…”

Genome Replikin Count Predicts Increased Lethality of Cancer

“…Exclusions. Sera were not sent from patients with known advanced or terminal cancer, since it had been previously established 51,53 that due to antibody failure, antimalignin antibody concentration is reduced to the 'normal' range in these cases. 46 patients with breast disorders for whom clinical information was not available (3.8% of total breast cases) were excluded because the diagnosis (benign vs. malignant) was unknown.…”

“…The antigen markers detected only between 0 and 16%: CEA-0%, CA19.9-5%, CA15.3-11%, CA125-16%, whereas antimalignin detected 95% of breast cancers 1mm to 10 mm in size pre-biopsy. Antimalignin is most sensitive in the early stages of breast malignancy and less sensitive as the cancer progresses to advanced and terminal stages when the antibody response is interfered with and antibody increase cannot be used as an aid to diagnosis 51,53,61 . Due to failure of this antibody, 'normal' antimalignin concentrations are observed in almost all cases of advanced and terminal malignancy 61 .…”

“…In the present study, even one elevated antimalignin is counted as positive, while in most antigen marker studies, two consecutive elevations are required before assigning a positive value8. Since the antimalignin false positive rate is from 0 to 3% in different non-tumor pathological groups and healthy controls 51,53,61 , the antimalignin test can be useful in combination with the antigen marker tests like PSA which have false positive rates up to 70% [27][28][29] .…”